GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:19 2024-05-17 am EDT 5-day change 1st Jan Change
1,775 GBX -0.48% Intraday chart for GSK plc -0.31% +22.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UK's FTSE 100 Closes Lower Amid Inflation Focus MT
Marti Technologies Hires Oguz Erkan as CFO MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion MT
FTSE 100 slides; Eurozone inflation steady AN
London stocks dip as global rates outlook weighs RE
GSK: sale of remaining stake in Haleon CF
GSK sells remaining Haleon stake for GBP1.25 billion AN
FTSE 100 lacklustre as Wall Street rally ends AN
London stocks lacklustre but set for weekly gains RE
Land Securities ups dividend; GSK sells Haleon stake AN
GSK Divests Remaining Haleon Stake in GBP1.25 Billion Deal MT
GSK Sells Last Haleon Shares for $1.58 Billion DJ
GSK raises $1.5 bln from sale of remaining Haleon stake RE
GSK Raises About 1.25 Bln Stg Via Haleon Stake Sale RE
GSK: FOLLOWING SETTLEMENT OF PLACING, GSK WILL HAVE FULLY EXITED… RE
GSK: AGREED TO SELL 385,320,110 ORDINARY SHARES IN HALEON AT A P… RE
GSK to Sell Remaining Haleon Stake MT
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update DJ
GSK intends to sell its remaining stake in Haleon RE
GSK to Sell Stake in Haleon Valued at About $1.61 Billion DJ
GSK to sell remaining holding in spin-off Haleon AN
GSK Plans to Sell 385 Million Haleon Shares MT
GSK Plans to Sell About 385 Million Haleon Shares, Bloomberg Reports MT
GSK intends to sell its entire stake in Haleon RE
Europe struggles but record highs in New York AN
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.75 GBP
Average target price
20.32 GBP
Spread / Average Target
+14.50%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW